Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy combo aims to boost stomach cancer survival after surgery

NCT ID NCT03221426

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy before and after surgery helps people with stomach or gastroesophageal junction cancer. Over 1,000 participants received either pembrolizumab plus chemo or placebo plus chemo. The study measured how long patients lived without the cancer coming back and whether the cancer completely disappeared at surgery. Results will show if this combination improves outcomes compared to chemo alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pembrolizumab (Keytruda) plus chemotherapy (capecitabine, cisplatin, 5-fluorouracil, or docetaxel/oxaliplatin/leucovorin)
What this could lead to
If successful, this could lead to a new standard treatment that improves survival and increases the chance of eliminating all cancer before and after surgery for stomach and GEJ cancer.
What could go wrong
This is a large phase 3 trial, but results may show only modest benefit over chemo alone. Pembrolizumab can cause immune-related side effects, and not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,007 people

The number who actually took part.

Started

Oct 2017

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has previously untreated localized gastric or GEJ adenocarcinoma as defined by T3 or greater primary lesion or the presence of any positive nodes - N+ (clinical nodes) without evidence of metastatic disease. * Plans to proceed to surgery following pre-operative chemotherapy based on standard staging studies per local practice. * Is willing to provide tissue from a tumor lesion at baseline and at time of surgery. * Has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1 within 3 days prior to the first dose of study treatment. * Has adequate organ function. * Male participants of childbearing potential must agree to use an adequate method of contraception for the course of the study through 180 days after the last dose of chemotherapy. * Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 180 days after the last dose of chemotherapy or through 120 days after the last dose of pembrolizumab, whichever is greater. * Has life expectancy of greater than 6 months. Exclusion Criteria: * Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis. * Has an active infection requiring systemic therapy. * Is currently participating in or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment. * Has received prior therapy with an anti-programmed cell death protein-1 (anti-PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (i.e., cytotoxic T-lymphocyte-associated protein 4 \[CTLA-4\], tumor necrosis factor receptor superfamily member 4 \[OX-40\], necrosis factor receptor superfamily member 9 \[CD137\]) or has previously participated in a MSD pembrolizumab (MK-3475) clinical study. * Has received prior systemic anti-cancer therapy including investigational agents for the current malignancy. * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 14 days prior the first dose of study treatment. * Has a known additional malignancy that is progressing or has required active treatment within the past 5 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ that have undergone potentially curative therapy are not excluded. * Has a known severe hypersensitivity (≥ Grade 3) to pembrolizumab, its active substance and/or any of its excipients, or to any of the study chemotherapy agents and/or to any of their excipients. * Has an active autoimmune disease that has required systemic treatment in past 2 years. * Has a known history of human immunodeficiency virus (HIV) infection. * Has a known history of Hepatitis B or known active Hepatitis C virus infection. * Has a known history of active tuberculosis (TB). * Female participants who are pregnant or breastfeeding or expecting to conceive children within the projected duration of the study, starting with the screening visit through180 days after the last dose of chemotherapy or through 120 days after the last dose of pembrolizumab, whichever is greater. * Male participants who are expecting to father children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of chemotherapy. * Has had an allogenic tissue/solid organ transplant. * Has received a live vaccine within 30 days prior to the first dose of study treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal cancer gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric cancer Gastroesophageal junction cancer

Contacts and locations

Locations

  • A.O.U. Santa Maria della Misericordia di Udine ( Site 0434)

    Udine, 33100, Italy

  • AZ Groeninge ( Site 0481)

    Kortrijk, West-Vlaanderen, 8500, Belgium

  • Aichi Cancer Center Hospital ( Site 0165)

    Nagoya, Aichi-ken, 464-8681, Japan

  • Asan Medical Center ( Site 0082)

    Seoul, 05505, South Korea

  • Azienda Ospedaliero Universitaria di Modena Policlinico ( Site 0429)

    Modena, 41125, Italy

  • Beijing Cancer Hospital ( Site 0221)

    Beijing, Beijing Municipality, 100142, China

  • Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 0354)

    Bielsko-Biala, Silesian Voivodeship, 43-300, Poland

  • Blokhin National Medical Oncology ( Site 0494)

    Moscow, Moscow, 115478, Russia

  • CEPON - Centro de Pesquisas Oncologicas ( Site 0302)

    Florianópolis, Santa Catarina, 88034-000, Brazil

  • CHRU Lille - Hopital Claude Huriez ( Site 0461)

    Lille, Nord, 59037, France

  • CHU Brest - Institut de Cancerologie et d Hematologie ( Site 0474)

    Brest, Finistere, 29200, France

  • CHU Hopital Saint Antoine ( Site 0471)

    Paris, 75012, France

  • CHU Poitiers - Pole Regional de Cancerologie ( Site 0467)

    Poitiers, Vienne, 86021, France

  • CHU Reims - Hopital Robert Debre ( Site 0465)

    Reims, Champagne-Ardenne, 51092, France

  • CHU Toulouse - Hopital Rangueil ( Site 0470)

    Toulouse, Haute-Garonne, 31059, France

  • CHU UCL Namur Site de Godinne ( Site 0485)

    Yvoir, Namur, 5530, Belgium

  • CHU de Liege ( Site 0482)

    Liège, Liege, 4000, Belgium

  • CHU de Quebec - Hotel-Dieu de Quebec ( Site 0042)

    Québec, Quebec, G1R 2J6, Canada

  • CISSS de la Monteregie-Centre ( Site 0039)

    Greenfield Park, Quebec, J4V 2H1, Canada

  • CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0040)

    Montreal, Quebec, H1T 2M4, Canada

  • CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0035)

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Centre Eugene Marquis ( Site 0466)

    Rennes, Ille-et-Vilaine, 35042, France

  • Centro Medico Integral De Cancerología (CEMIC) ( Site 0260)

    Quetzaltenango, 09002, Guatemala

  • Chang Gung Medical Foundation. Linkou ( Site 0064)

    Taoyuan, 333, Taiwan

  • Chiba Cancer Center ( Site 0180)

    Chiba, 260-8717, Japan

  • Chonnam National University Hwasun Hospital ( Site 0083)

    Hwasun Gun, Jeonranamdo, 58128, South Korea

  • City Clinical Hosp.4 of DCC ( Site 0325)

    Dnipro, Dnipropetrovsk Oblast, 49102, Ukraine

  • City clinical oncological dispensary ( Site 0336)

    Saint Petersburg, Sankt-Peterburg, 198255, Russia

  • City of Hope ( Site 0005)

    Duarte, California, 91010, United States

  • Communal non profit enterprise Regional Clinical Oncology Center ( Site 0591)

    Kharkiv, Kharkiv Oblast, 61070, Ukraine

  • Cross Cancer Institute ( Site 0033)

    Edmonton, Alberta, T6G 1Z2, Canada

  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0430)

    Milan, Lombardy, 20133, Italy

  • Fox Chase Cancer Center ( Site 0006)

    Philadelphia, Pennsylvania, 19111, United States

  • Fundacao Pio XII - Hospital de Cancer de Barretos ( Site 0301)

    Barretos, São Paulo, 14784-400, Brazil

  • Fundacion Arturo Lopez Perez FALP ( Site 0286)

    Santiago, Region M. de Santiago, 7500921, Chile

  • Gachon University Gil Medical Center ( Site 0087)

    Incheon, 21565, South Korea

  • Gangnam Severance Hospital ( Site 0088)

    Seoul, 06273, South Korea

  • Georgetown University ( Site 0015)

    Washington D.C., District of Columbia, 20007, United States

  • Gifu University Hospital ( Site 0166)

    Gifu, 501-1194, Japan

  • Grand Hopital de Charleroi ( Site 0478)

    Charleroi, Hainaut, 6000, Belgium

  • Grupo Medico Angeles ( Site 0261)

    Guatemala City, 01015, Guatemala

  • Hadassah Medical Center. Ein Kerem ( Site 0383)

    Jerusalem, 9112001, Israel

  • Haematologisch-Onkologische Praxis Eppendorf Facharztzentrum Eppendorf - Hope ( Site 0454)

    Hamburg, 20249, Germany

  • Hiroshima City Hiroshima Citizens Hospital ( Site 0171)

    Hiroshima, 730-8518, Japan

  • Hokkaido University Hospital ( Site 0160)

    Sapporo, Hokkaido, 060-8648, Japan

  • Hopital Erasme ULB ( Site 0484)

    Brussels, Bruxelles-Capitale, Region de, 1070, Belgium

  • Hopital Prive Jean Mermoz ( Site 0462)

    Lyon, Auvergne, 69008, France

  • Hospital Clinico Universidad de Chile ( Site 0287)

    Santiago, Region M. de Santiago, 8380456, Chile

  • Hospital Israelita Albert Einstein ( Site 0309)

    São Paulo, 05652-900, Brazil

  • Hospital Kuala Lumpur ( Site 0146)

    Kuala Lumpur, 50586, Malaysia

  • Hospital Regional Rancagua Libertador Bernardo O Higgins ( Site 0299)

    Rancagua, Lbtdr Gen Bernardo O Higgins, 2820000, Chile

  • Hospital de Base de Sao Jose de Rio Preto ( Site 0304)

    Sao Jose Rio Preto, São Paulo, 15090-000, Brazil

  • Hyogo Cancer Center ( Site 0182)

    Akashi, Hyōgo, 673-8558, Japan

  • IRCCS Istituto Oncologico Veneto ( Site 0431)

    Padova, Abruzzo, 35128, Italy

  • IRCCS Policlinico San Donato ( Site 0433)

    San Donato Milanese, Milano, 20097, Italy

  • Ibaraki Prefectural Central Hospital ( Site 0177)

    Kasama, Ibaraki, 309-1793, Japan

  • Imperial College Healthcare NHS Trust ( Site 0402)

    London, London, City of, W2 1NY, United Kingdom

  • Institut Jules Bordet ( Site 0480)

    Brussels, Bruxelles-Capitale, Region de, 1000, Belgium

  • Institut Mutualiste Montsouris ( Site 0463)

    Paris, 75014, France

  • Institut Paoli Calmettes ( Site 0472)

    Marseille, Bouches-du-Rhone, 13009, France

  • Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 0469)

    Saint-Herblain, Loire-Atlantique, 44805, France

  • Institut du Cancer de Montpellier ( Site 0473)

    Montpellier, Herault, 34298, France

  • Instituto Clinico del Sur. ICOS ( Site 0290)

    Temuco, Araucania, 4810469, Chile

  • Instituto Nacional Do Cancer Jose Alencar Gomes Da Silva ( Site 0307)

    Rio de Janeiro, 20230-130, Brazil

  • Instituto do Cancer do Ceara ( Site 0311)

    Fortaleza, Ceará, 60430-230, Brazil

  • Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0305)

    São Paulo, 01246-000, Brazil

  • Integra Cancer Institute ( Site 0262)

    Guatemala City, 01010, Guatemala

  • Istituto Clinico Humanitas Research Hospital ( Site 0432)

    Rozzano, Milano, 20089, Italy

  • Ivano-Frankivsk Regional Oncology Clinical Dispensary ( Site 0321)

    Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76018, Ukraine

  • Iwate Medical University Hospital ( Site 0184)

    Shiwa-gun, Iwate, 028-3695, Japan

  • Jewish General Hospital ( Site 0034)

    Montreal, Quebec, H3T 1E2, Canada

  • Kaluga Regional Clinical Oncology Center ( Site 0345)

    Kaluga, Kaluzskaja Oblast, 248007, Russia

  • Kanagawa Cancer Center ( Site 0167)

    Yokohama, Kanagawa, 241-8515, Japan

  • Kansai Medical University Hospital ( Site 0190)

    Hirakata, Osaka, 573-1191, Japan

  • Kliniken Essen Mitte Gmbh Evang. Huyssens Stiftung ( Site 0445)

    Essen, North Rhine-Westphalia, 45136, Germany

  • Klinikum Esslingen GmbH ( Site 0453)

    Esslingen am Neckar, Baden-Wurttemberg, 73730, Germany

  • Klinikum der Universitaet in Muenchen ( Site 0446)

    Munich, Bavaria, 81377, Germany

  • Kobe City Medical Center General Hospital ( Site 0181)

    Kobe, Hyōgo, 650-0047, Japan

  • Kobe University Hospital ( Site 0188)

    Kobe, Hyōgo, 650-0017, Japan

  • Kochi Health Sciences Center ( Site 0189)

    Kochi, 781-8555, Japan

  • Koo Foundation Sun Yat-Sen Cancer Center ( Site 0066)

    Taipei, 11259, Taiwan

  • Korea University Anam Hospital ( Site 0084)

    Seoul, 02841, South Korea

  • Kumamoto University Hospital ( Site 0164)

    Kumamoto, 860-8556, Japan

  • Kyiv City Clinical Oncology Center ( Site 0590)

    Kyiv, Kyivska Oblast, 03115, Ukraine

  • Kyungpook National University Chilgok Hospital ( Site 0089)

    Daegu, Taegu-Kwangyokshi, 41404, South Korea

  • Kyushu University Hospital ( Site 0173)

    Fukuoka, 812-8582, Japan

  • LSMUL Kauno Klinikos ( Site 0570)

    Kaunas, 50161, Lithuania

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0019)

    New York, New York, 10016, United States

  • Leningrad Regional Oncology Center ( Site 0335)

    Saint Petersburg, Sankt-Peterburg, 188663, Russia

  • MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council ( Site 0589)

    Kryviy Rih, Dnipropetrovsk Oblast, 50048, Ukraine

  • Mackay Memorial Hospital ( Site 0065)

    Taipei, 104, Taiwan

  • Mazowiecki Szpital Onkologiczny ( Site 0363)

    Wieliszew, Masovian Voivodeship, 05-135, Poland

  • Medizinische Hochschule Hannover ( Site 0449)

    Hanover, Lower Saxony, 30625, Germany

  • Medizinische klinilk und Poliklinik Johannes Gutenberg Univ ( Site 0455)

    Mainz, Rhineland-Palatinate, 55131, Germany

  • Meir medical center ( Site 0386)

    Kfar Saba, Central District, 4428164, Israel

  • Memorial Sloan Kettering ( Site 0024)

    New York, New York, 10065, United States

  • Moncton Hospital - Horizon Health Network ( Site 0038)

    Moncton, New Brunswick, E1C 6Z8, Canada

  • Nacionalinis Vezio Institutas ( Site 0569)

    Vilnius, 08406, Lithuania

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0349)

    Warsaw, Masovian Voivodeship, 02-034, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0361)

    Gliwice, Silesian Voivodeship, 44-101, Poland

  • National Cancer Center Hospital ( Site 0179)

    Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East ( Site 0178)

    Kashiwa, Chiba, 277-8577, Japan

  • National Cancer Centre Singapore ( Site 0097)

    Singapore, Central Singapore, 169610, Singapore

  • National Cancer Institute of the MoH of Ukraine ( Site 0319)

    Kyiv, Kyivska Oblast, 03022, Ukraine

  • National Cheng Kung University Hospital ( Site 0067)

    Tainan, 704, Taiwan

  • National Hospital Organization Kyushu Cancer Center ( Site 0172)

    Fukuoka, 811-1395, Japan

  • National Hospital Organization Shikoku Cancer Center ( Site 0186)

    Matsuyama, Ehime, 791-0280, Japan

  • National Medical and Surgical Center n.a. N.I.Pirogov ( Site 0338)

    Moscow, Moscow, 105203, Russia

  • National Taiwan University Hospital ( Site 0063)

    Taipei, 10002, Taiwan

  • National University Hospital ( Site 0095)

    Singapore, Central Singapore, 119074, Singapore

  • Niigata Cancer Center Hospital ( Site 0169)

    Niigata, 951-8566, Japan

  • Ninewells Hospital and Medical School ( Site 0406)

    Dundee, Dundee City, DD1 9SY, United Kingdom

  • Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0018)

    Chicago, Illinois, 60611, United States

  • Oncocare Cancer Centre ( Site 0096)

    Singapore, Central Singapore, 258499, Singapore

  • Osaka General Medical Center ( Site 0159)

    Osaka, 558-8558, Japan

  • Osaka International Cancer Institute ( Site 0161)

    Osaka, 541-8567, Japan

  • Osaka Medical College Hospital ( Site 0168)

    Takatsuki, Osaka, 569-8686, Japan

  • Osaka University Hospital ( Site 0162)

    Suita, Osaka, 565-0871, Japan

  • Pontificia Universidad Catolica de Chile ( Site 0285)

    Santiago, Region M. de Santiago, 8330032, Chile

  • Rabin-Medical Center ( Site 0384)

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus ( Site 0381)

    Haifa, 31096, Israel

  • Riga East Clinical University Hospital ( Site 0550)

    Riga, 1079, Latvia

  • Roswell Park Cancer Institute ( Site 0001)

    Buffalo, New York, 14263, United States

  • Royal Free London NHS Foundation Trust ( Site 0403)

    London, London, City of, NW3 2QG, United Kingdom

  • Royal Marsden NHS Foundation Trust ( Site 0400)

    Sutton, Surrey, SM2 5PT, United Kingdom

  • SA Pohja-Eesti Regionaalhaigla ( Site 0526)

    Tallinn, Harju, 13419, Estonia

  • SBHI Leningrad Regional Clinical Hospital ( Site 0496)

    Saint Petersburg, Leningradskaya Oblast', 194291, Russia

  • SMG-SNU BORAMAE Medical Center ( Site 0086)

    Seoul, 07061, South Korea

  • SPZOZ WSS nr 3 w Rybniku ( Site 0357)

    Rybnik, Silesian Voivodeship, 44-200, Poland

  • Saitama Cancer Center ( Site 0170)

    Kitaadachi-gun, Saitama, 362-0806, Japan

  • Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie ( Site 0351)

    Lublin, Lublin Voivodeship, 20-080, Poland

  • Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 0344)

    Saint Petersburg, Sankt-Peterburg, 197758, Russia

  • Seconda Universita Napoli ( Site 0436)

    Naples, 80131, Italy

  • Seoul National University Bundang Hospital ( Site 0085)

    Seongnam-si, Kyonggi-do, 13620, South Korea

  • Seoul National University Hospital -SNUH- ( Site 0080)

    Seoul, 03080, South Korea

  • Severance Hospital Yonsei University Health System ( Site 0081)

    Seoul, 03722, South Korea

  • Sheba Medical center ( Site 0387)

    Ramat Gan, 5265601, Israel

  • Shizuoka Cancer Center Hospital and Research Institute ( Site 0176)

    Sunto-gun, Shizuoka, 411-8777, Japan

  • Sir Run Run Shaw Hospital ( Site 0233)

    Hangzhou, Zhejiang, 430030, China

  • Soroka University M.C ( Site 0385)

    Beersheba, Southern District, 8410101, Israel

  • Sourasky Medical Center. ( Site 0382)

    Tel Aviv, Tell Abib, 6423906, Israel

  • St. Luke s Medical Center ( Site 0622)

    Quezon City, National Capital Region, 1102, Philippines

  • St. Marianna University School of Medicine Hospital ( Site 0187)

    Kawasaki, Kanagawa, 216-8511, Japan

  • Sunnybrook Research Institute ( Site 0032)

    Toronto, Ontario, M4N 3M5, Canada

  • Szpital Specjalistyczny w Koscierzynie Sp. z o.o. ( Site 0353)

    Kościerzyna, Pomeranian Voivodeship, 83-400, Poland

  • Szpital Uniwersytecki w Krakowie ( Site 0352)

    Krakow, Lesser Poland Voivodeship, 31-501, Poland

  • Taipei Medical University Shuang Ho Hospital ( Site 0068)

    New Taipei City, 235, Taiwan

  • Temple University Hospital ( Site 0026)

    Philadelphia, Pennsylvania, 19140, United States

  • The Cancer Institute Hospital of JFCR ( Site 0185)

    Tokyo, 135-8550, Japan

  • The Christie NHS Foundation Trust ( Site 0397)

    Manchester, M20 4BX, United Kingdom

  • The Royal Marsden Foundation Trust ( Site 0405)

    London, London, City of, SW3 6JJ, United Kingdom

  • The University of Chicago Medical Center ( Site 0004)

    Chicago, Illinois, 60637, United States

  • Tokyo Metropolitan Komagome Hospital ( Site 0183)

    Tokyo, 113-8677, Japan

  • Tomsk Scientific Research Institute of Oncology ( Site 0337)

    Tomsk, Tomsk Oblast, 634028, Russia

  • Toyama Prefectural Central Hospital ( Site 0163)

    Toyama, 930-8550, Japan

  • UCL Saint Luc ( Site 0479)

    Brussels, Bruxelles-Capitale, Region de, 1200, Belgium

  • UZ Gent ( Site 0486)

    Ghent, Oost-Vlaanderen, 9000, Belgium

  • UZ Leuven ( Site 0483)

    Leuven, Vlaams-Brabant, 3000, Belgium

  • Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 0308)

    Porto Alegre, Rio Grande do Sul, 90610-000, Brazil

  • Universitaetsklinikum Carl Gustav Carus der TU Dresden ( Site 0448)

    Dresden, Saxony, 01307, Germany

  • Universitaetsklinikum Freiburg ( Site 0450)

    Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany

  • University Hospitals Bristol NHS Foundation Trust ( Site 0407)

    Bristol, Bristol, City of, BS2 8ED, United Kingdom

  • University Malaya Medical Centre ( Site 0143)

    Kuala Lumpur, 59100, Malaysia

  • University of Rochester ( Site 0011)

    Rochester, New York, 14642, United States

  • University of Utah, Huntsman Cancer Institute ( Site 0012)

    Salt Lake City, Utah, 84112, United States

  • Vilniaus Universiteto Ligonine Santaros Klinikos ( Site 0568)

    Vilnius, 08460, Lithuania

  • Virginia Cancer Specialists, PC ( Site 0010)

    Fairfax, Virginia, 22031, United States

  • Weill Cornell Medical Center ( Site 0023)

    New York, New York, 10065, United States

  • Wojewodzki Szpital Specjalistyczny we Wroclawiu ( Site 0358)

    Wroclaw, Lower Silesian Voivodeship, 51-124, Poland

  • Yale Cancer Center ( Site 0016)

    New Haven, Connecticut, 06520, United States

  • Zhejiang Cancer Hospital ( Site 0231)

    Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.